Hikma signs agreement for marketing of anti-cancer compound
22nd Oct 2012 12:26
FTSE 250 group Hikma Pharmaceuticals has signed an agreement for the registration and marketing of Lutrate 1 month, GP Pharm's anti-cancer compound, for the Middle East and North Africa (MENA) region. Lutrate 1 month is a hormonal androgen deprivation therapy used to prevent tumor growth in patien
Read moreMonday broker round-up - UPDATE
22nd Oct 2012 08:19
888 Holdings: Morgan Stanley ups target from 125p to 130p, overweight rating kept. Aggreko: Jefferies cuts target from 2,800p to 2,535p, buy rating kept; HSBC downgrades to underweight, target cut from 2,350p to 1,750p; JPMorgan Cazenove cuts target from 2,360p to 2,165p, neutral rating kept; Barcl
Read moreLondon close: Markets nervous ahead of Jackson Hole
29th Aug 2012 16:39
- Stocks look to Jackson Hole summit for a boost - Draghi hints at action ahead of ECB meeting - Glencore leads fallers on growing opposition to merger Global stock markets were mostly trading in the red on Wednesday afternoon in spite an upwards revision to US economic growth as investors showed c
Read moreLondon midday: Markets look to Jackson Hole for boost
29th Aug 2012 11:37
- Greece agrees on budget plan - Spain a concern as Catalonia in need of aid - Markets look ahead to Jackson Hole meeting The Footsie remained firmly in the red in morning trade as concerns over the Eurozone and speculation about the upcoming Jackson Hole meeting in Wyoming continue to be the focus
Read moreLondon open: Glencore leads fallers early on
29th Aug 2012 08:25
- Spain a concern as Catalonia needs aid - Markets await Bernanke - Ex-div Glencore a heavy faller early on Ex-div stocks and miners were weighing heavily on the FTSE 100 index in early trading on Wednesday morning with worries about Spain weighing on sentiment. It was revealed yesterday that the
Read moreMonday broker round-up -UPDATE
20th Aug 2012 08:17
AstraZeneca: JPMorgan Cazenove downgrades to underweight, target lifted from 2,800p to 2,970p. Balfour Beatty: JPMorgan Cazenove downgrades to neutral. Barclays: Citigroup reiterates buy and 330p target price. ENRC: Credit Suisse downgrades to neutral, target cut from 500p to 450p. FirstGroup: J
Read moreFriday tips round-up: Hikma, African Barrick, Lenovo
17th Aug 2012 06:58
What a difference a year makes, Tempus in The Times proclaims. When the Arab Spring was in full flow, investors worried that Hikma Pharmaceuticals was too exposed to the unstable region. The company, based in Jordan, almost halved last year's sales growth forecast as governments fell. Now it looks w
Read moreBroker tips: ENRC, Hikma, Micro Focus
16th Aug 2012 12:10
UBS has cut its target price for mining group Eurasian Natural Resources Corp (ENRC) from 585p to 565p after first-quarter figures came in below expectations. UBS has reduced its 2012 and 2013 EPS estimates by 4% and 7%, respectively, mainly on the back of a higher tax rate (which moderates from 20
Read moreLondon midday: Stocks fall despite retail data and stimulus hopes
16th Aug 2012 11:46
- UK retail sales beat estimates in July - Investors eye US data - Chinese stimulus hopes increase After a pretty subdued start, the Footsie had fallen further into the red by Thursday lunchtime in spite of some better-than-expected UK retail sales data. Sales volumes rose by 0.3% during July, up
Read moreBroker snap: Jefferies hails injectables performance at Hikma
16th Aug 2012 11:25
Jefferies has maintained its 'buy' rating and 860p target price for pharmaceuticals group Hikma after the firm's first-half results came in above forecasts, driven by a better-than-expected performance from the Injectables division. Group sales gained 34.8% to $532.3m in the first six months of the
Read moreThursday broker round-up
16th Aug 2012 10:06
Aegis: UBS downgrades to neutral. Babcock: Espirito Santo downgrades to neutral. Balfour Beeatty: HB Markets downgrades to hold; Deutsche Bank downgrades to hold. BG Group: Morgan Stanley downgrades to equal weight. Capital Shopping Centres: Oriel Securities upgrades to hold. Carclo: N+1 Brewin
Read moreLondon open: Mixed start; African Barrick jumps
16th Aug 2012 08:39
- African Barrick up as China Gold shows interest - Markets continue to sift through global economic data - Wen sees 'growing room for policy operation' London's benchmark index was broadly flat on Thursday morning as investors continue to digest a raft of economic data that has been released over
Read moreLondon pre-open: Stimulus hopes to boost Footsie
16th Aug 2012 07:26
City sources predict the FTSE 100 will open up 17 points from yesterday's close of 5,833, boosted by hopes of further economic stimulus from central banks across the globe. Overnight China revealed that its foreign direct investment declined 8.7% to $7.6bn in July, compared to the same month the p
Read moreHikma reiterates revenue guidance
16th Aug 2012 07:11
Revenue from generic drugs fell in the first half at Hikma Pharmaceuticals but branded products more than picked up the slack. Overall, revenue in the first half of 2012 rose 34.8% to $532.3m from $394.8m the year before, helped by contributions from recent acquisitions. Organic revenue growth was
Read moreThursday preview: Hikma, PV Crystalox, retail sales
15th Aug 2012 17:57
Acquisitions are set to put a gloss on the interim results of pharmaceuticals firm Hikma on Thursday. Peel Hunt is expecting the group to report sales of more than $500m, up 25% on the first half of last year when, admittedly, results had been negatively affected by the so-called Arab Spring. Sale
Read more